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REPLY
We thank Dr. Shanmugam for his interest in our study (1). Most
of the limitations he raises have been discussed in detail in our
report. We have never suggested that a cutoff of 40 mm Hg was
equivalent to severe pulmonary hypertension. Nonetheless, as we
have also alluded to in our study, such levels of pulmonary
pressures, equivalent to mild/moderate pulmonary hypertension,
have been associated with significantly worse outcomes. Moreover,
the fact that such levels of pressure would persist in patients with
prosthesis-patient mismatch (PPM), whereas they would regress in
most patients without PPM, indeed confirms that levels above 40
mm Hg are clearly abnormal.
The indexed effective orifice area (EOA) is a physiological
parameter that relates to the intrinsic hemodynamic performance
of the prosthesis and has nothing to do with valve annular
diameters. The threshold value of 1.2 cm2/m2 was chosen to
identify PPM because it was the most discriminative value to
identify patients with persisting pulmonary artery hypertension
after mitral valve replacement (MVR), and it is consistent with
previous in vitro and in vivo studies on mitral PPM. As we have
emphasized, the pressure gradient is a much less appropriate
parameter with which to assess the consequences of PPM, espe-
cially in the mitral position, because it is highly influenced by
chronotropic conditions and because mitral flow tends to decrease
when pulmonary resistances are increased.
The statement that “the minimum absolute valve EOA of any
size-23 prosthesis is 2.54 cm2” denotes a gross misunderstanding
of valve prosthesis physiology and is equivalent to saying that all
prostheses of a given labeled size would have similar hemodynamic
performance. Indeed, it is well known that labeled sizes have no
relevance to valve hemodynamics and that they grossly overesti-
mate the actual EOA, which may vary from one type of prosthesis
to another. In this context, it is interesting to note that the normal
reference values of EOA for 27-mm mitral prostheses range from
1.6 to 2.2 cm2 (2). Hence, it is not surprising that PPM defined as
an indexed EOA 1.2 cm2/m2 can be a frequent occurrence in
patients undergoing MVR.
We agree with Dr. Shanmugam that the prevention of PPM in
the mitral position is a particularly demanding challenge for the
surgeon and that there are not as many options as in the aortic
position. Nonetheless, and as we have shown, it is not a rare
occurrence and definitely warrants further documentation. Our
results also provide impetus for the development of better per-
forming mitral prostheses.
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Drug-Eluting Stent
Thrombosis: A Pooled Analysis
With great interest I read the study by Moreno et al. (1) regarding
drug-eluting stent thrombosis. The investigators showed a signif-
icant relation between the rate of drug-eluting stent thrombosis
and the mean stented length in each trial. However, the mean
stented length may not represent the stent length of the actual
cases, especially in these few occurrences of thrombosis (0.5%).
In their study, only 15 cases suffered from drug-eluting stent
thrombosis. Collecting individual patient data will provide the least
biased and most reliable means of addressing questions (2).
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We thank Dr. Kaneda for his interest in our study. We agree with
the affirmation that the mean stented length for each study may
not necessarily represent the stent length of the actual cases of stent
thrombosis. Because of that, as we described in the Methods
section (Statistical Analysis), we contacted the principal investiga-
tors of all studies in which at least one drug-eluting stent
thrombosis was documented, requesting the total stent length for
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each of these cases (1). As we already reported in our study, the
mean stented length for cases with drug-eluting stent thrombosis
was 23.4 mm, which was significantly longer than that in those
patients not suffering stent thrombosis (21.3 mm), thus confirming
that the total stented length is related to the risk of thrombosis
after drug-eluting stent implantation.
Moreover, our data are consistent with other studies that have
also shown a significant relationship between stent length and the
risk of stent thrombosis, both with bare-metal (2) and drug-eluting
stents (3,4).
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